TransMedics Group Q2 2024 Earnings Report $61.70 +1.17 (+1.93%) (As of 12/20/2024 05:51 PM ET) Earnings HistoryForecast TransMedics Group EPS ResultsActual EPS$0.35Consensus EPS $0.21Beat/MissBeat by +$0.14One Year Ago EPS-$0.03TransMedics Group Revenue ResultsActual Revenue$114.30 millionExpected Revenue$98.84 millionBeat/MissBeat by +$15.46 millionYoY Revenue Growth+117.70%TransMedics Group Announcement DetailsQuarterQ2 2024Date7/31/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseTMDX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. TransMedics Group Earnings HeadlinesTransMedics Group (NASDAQ:TMDX) Earns Neutral Rating from JPMorgan Chase & Co.December 19 at 1:58 AM | americanbankingnews.comJP Morgan Downgrades TransMedics Group (TMDX)December 17, 2024 | msn.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 21, 2024 | Crypto Swap Profits (Ad)William Blair Cuts Earnings Estimates for TransMedics GroupDecember 14, 2024 | americanbankingnews.comQ3 EPS Estimate for TransMedics Group Boosted by AnalystDecember 14, 2024 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low After Analyst DowngradeDecember 14, 2024 | americanbankingnews.comSee More TransMedics Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TransMedics Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransMedics Group and other key companies, straight to your email. Email Address About TransMedics GroupTransMedics Group (NASDAQ:TMDX), a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.View TransMedics Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
